62 pharmaceutical companies announced their annual results, with 5 having a net profit of more than 1 billion yuan

[industry trends of pharmaceutical network] by the middle of January 2019, according to statistics, 62 pharmaceutical enterprises have issued the full year performance forecast for 2019, including 10 enterprises expected to lose money, with a loss area of about 16.13%, 50 enterprises expected to make profit, about 80.65%, and 2 uncertain enterprises It is worth noting that five of them have predicted a net profit of more than 1 billion yuan for the whole year Next, let me take you into these five enterprises Zhifei biology: the estimated net profit is 2.539 billion yuan On January 3, Zhifei biology issued the announcement of performance increase in advance It is estimated that the net profit attributable to shareholders of Listed Companies in 2019 is 2249.6181 million yuan to 2539.8914 million yuan, up 55% - 75% over the same period of last year In fact, this is also the first time that the market value of Zhifei biology has exceeded 90 billion yuan since it was listed nine years ago, and it is the first one to stabilize the A-share vaccine sector   As for the reason of high performance growth, the announcement disclosed that the company continued to focus on vaccine and biological products research and development, production, sales, promotion, distribution and import vaccine agency in 2019, and steadily promoted various works The product sales progressed smoothly, and completed the annual production and operation plan, and the company's main business income, net profit and other important financial indicators Compared with the same period of last year, there was a better growth In fact, since the "rocket speed" of the four price HPV vaccine and the nine price HPV vaccine entered China, as the mainland agent of these two heavyweight products, it is conceivable that the performance of Zhifei biology can blowout CR Sanjiu: the estimated net profit is RMB 2.250 billion Prior to that, according to the announcement issued by CR Sanjiu, the expected net profit attributable to shareholders of listed companies from January to December 2019 is RMB 2.11 billion to RMB 2.250 billion, with a year-on-year change of 47.34% to 57.11%, and the average growth rate of net profit of traditional Chinese medicine industry is 4.14% It is understood that at present, Cr 39 mainly has two businesses: self diagnosis and treatment and prescription medicine The former covers nearly 10 categories, such as cold, skin, gastrointestinal, cough relief, orthopedics, pediatrics, etc.; the latter covers the treatment fields of tumor, cardio cerebrovascular, digestive system, orthopedics, pediatrics, etc Since last year, despite frequent changes in the management of Cr 39, the overall performance is still good in terms of financial data Hualan biology: the net profit is estimated to be 1.368 billion yuan On January 6, Hualan biology issued a forecast on the performance of 2019 It is estimated that the profit last year was 1.25 billion yuan to 1.37 billion yuan, with a year-on-year growth range of 10% to 20% According to the announcement, there are two reasons for the growth of Hualan bio's performance in 2019 compared with that in 2018: first, the company's blood products business maintained a stable growth; second, the company's holding subsidiary Hualan bio vaccine Co., Ltd (vaccine company) saw a significant increase in the sales revenue of quadrivalent influenza vaccine Changchun hi tech: the net profit is estimated to be 1.360 billion yuan On January 2, Changchun hi tech issued the 2019 performance forecast The company expects to achieve the net profit attributable to the parent of 1.61 billion yuan to 1.812 billion yuan in 2019, a year-on-year increase of 60% to 80% over the same period of last year of 1.006 billion yuan The main business of Changchun hi tech is R & D, production and sales of biopharmaceuticals and proprietary Chinese medicines, supplemented by real estate development, property management and real estate leasing For the reason of this performance growth, it said that the main reason is the income growth of the holding backbone pharmaceutical enterprises, and the settlement income of the real estate development projects increased year on year; in addition, the company completed the acquisition of 29.5% minority shareholders' equity of kinsay pharmaceutical industry in November 2019, which was calculated as per the 99.5% shareholding ratio since November 2019 Lizhu group: the net profit is estimated to be 1.353 billion yuan In the recent 2019 performance express published by Lizhu group, the profit in 2019 is expected to be 1.245 billion yuan to 1.353 billion yuan, an increase of 15% to 25% year on year According to the announcement, through the continuous deepening of marketing system reform and the implementation of refined management, the profit growth of chemical preparation business sector is significantly faster than that of the previous year; in addition, due to the rapid growth of high-end characteristic API business and the cost reduction brought by process improvement, the profit of raw material medicine business sector is also significantly increased